Adcetris trial data against relapsed Hodgkin's published in JCO

Adcetris

According to Seattle Genetics, the Journal of Clinical Oncology is publishing results from a pivotal clinical trial of Adcetris (SGN-35) in patients with relapsed or refractory CD30-positive Hodgkin's lymphoma following an autologous stem cell transplantation.

This was an open-label, phase II study involving 102 patients.

Patients received Adcetris as a single agent and according to findings the antibody drug conjugate induced a durable objective response in 75% of patients and had an acceptable safety profile. 34 percent of patients in the study achieved complete remission.

The same medical journal will soon be publishing results from a separate clinical trial testing Adcetris in patients with relapsed or refractory anaplastic large cell lymphoma.

Source: MarketWatch

LymphomaInfo Social